journal
MENU ▼
Read by QxMD icon Read
search

Future Oncology

journal
https://www.readbyqxmd.com/read/28326839/entinostat-a-promising-treatment-option-for-patients-with-advanced-breast-cancer
#1
Roisin M Connolly, Michelle A Rudek, Richard Piekarz
Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer...
March 9, 2017: Future Oncology
https://www.readbyqxmd.com/read/28326838/ctla-4-gene-polymorphisms-associate-with-efficacy-of-postoperative-radioiodine-131-for-differentiated-thyroid-carcinoma
#2
De-Feng Chang, Xiao-Hong Chen, Jing Huang, Ya-Mei Sun, Da-Yong Zhu, Zhong-Qing Xu
AIM: To investigate the association of CTLA-4 polymorphisms with efficacy of postoperative radioiodine-131 (I-131) treatment for differentiated thyroid carcinoma (DTC). METHODS: A total of 324 DTC patients and 350 healthy individuals were enrolled in our study. Patients received I-131 remnant ablation following surgical resection. Based on the treatment efficacy, patients were divided into the effective (n = 183) and ineffective groups (n = 141). CTLA-4 polymorphisms (+49A>G, CT60A>G and -318C>T) were genotyped by polymerase chain reaction-restriction fragment length polymorphism...
March 3, 2017: Future Oncology
https://www.readbyqxmd.com/read/28326837/checkpoint-inhibitors-in-the-treatment-of-brain-metastases-of-non-small-cell-lung-cancer-and-melanoma
#3
Hampig Raphael Kourie, Hassan Kanaan, Gil Awada, Ahmad Hussein Awada
Brain metastases (BMs) are representing a new challenge for the oncologist; their incidence is increasing due to the better overall survival and systemic disease control in many malignancies, consequent to new potent cytotoxic and targeted therapies. In the era of immunotherapies, checkpoint inhibitors are representing a new therapeutic option in different solid tumors and settings; preliminary results showed potential activity of these agents in patients with BM, when administered as single agent or in combination with radiation therapy...
February 28, 2017: Future Oncology
https://www.readbyqxmd.com/read/28326836/clinical-significance-of-ndrg3-in-patients-with-breast-cancer
#4
Mehrdad Asghari Estiar, Ali-Akbar Zare, Rezvan Esmaeili, Leila Farahmand, Hassan Fazilaty, Davood Jafari, Tannaz Samadi, Keivan Majidzadeh-A
AIM: The expression level of NDRG3 gene is investigated among breast cancer (BC) patients. METHODS: Real-time quantitative PCR was performed. RESULTS:  NDRG3 was downregulated in BC patients particularly in advanced stage of the disease. HER2 status was significantly correlated with the expression of NDRG3. Also, triple-negative BC patients showed low levels of NDRG3 expression in comparison to other subtypes. Lastly, the expression of NDRG3 had significant impact on survival, with NDRG3 downregulated patients having the worst event-free survival rate among others...
February 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28326832/nintedanib-plus-docetaxel-as-second-line-therapy-in-patients-with-non-small-cell-lung-cancer-of-adenocarcinoma-histology-a-network-meta-analysis-vs-new-therapeutic-options
#5
Sanjay Popat, Anders Mellemgaard, Martin Reck, Claudia Hastedt, Ingolf Griebsch
PATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer. RESULTS: Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1...
February 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28326835/polymorphisms-of-cancer-stem-cell-marker-gene-cd133-are-associated-with-susceptibility-and-prognosis-of-gastric-cancer
#6
Zhi-Fang Jia, Yan-Hua Wu, Dong-Hui Cao, Xue-Yuan Cao, Jing Jiang, Bao-Sen Zhou
AIM: This study was aimed to investigate the associations between single nucleotide polymorphisms of cancer stem cell marker genes, CD44 and CD133, and susceptibility and prognosis of gastric cancer. PATIENTS & METHODS: Five single nucleotide polymorphisms in CD44 and CD133 genes were genotyped in 898 gastric cancer cases and 992 controls. RESULTS: The A/C or C/C genotypes of CD133 rs2240688 were associated with decreased risk of gastric cancer comparing with the A/A genotype (odds ratio: 0...
February 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28326834/thoracic-radiation-therapy-could-give-survival-benefit-to-elderly-patients-with-extensive-stage-small-cell-lung-cancer
#7
Changchun An, Wang Jing, Yan Zhang, Sujing Liu, Haiyong Wang, Kunli Zhu, Li Kong, Hongbo Guo, Hui Zhu
AIM: To evaluate the effect of thoracic radiation therapy (TRT) in elderly patients (aged ≥65 years) with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS & METHODS: This study reviewed the records of 118 elderly patients with ES-SCLC (all with distant metastasis) through January 2006-December 2013. The patients were divided into either a chemotherapy (ChT)/TRT-combination group or a ChT-alone group. RESULTS: The median survival time and 3-year overall survival rates in the ChT/TRT group were significantly higher than those in the ChT-alone group (17...
February 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28326833/efficacy-and-safety-of-eribulin-in-taxane-refractory-patients-in-the-real-world
#8
Vito Lorusso, Saverio Cinieri, Agnese Latorre, Luca Porcu, Lucia Del Mastro, Fabio Puglisi, Sandro Barni
AIM: Recent clinical, randomized and observational studies showed that eribulin, an analogous of Halichondrin B, was beneficial and well-tolerated in heavily pretreated metastatic breast cancer patients. Here, we aim to evaluate the effectiveness and safety of eribulin in taxane-refractory metastatic breast cancer patients. PATIENTS & METHODS: In this subanalysis of the ESEMPIO study database, we selected 91 subjects with well-defined taxane refractoriness and complete data available...
February 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28183198/doxorubicin-resistant-osteosarcoma-novel-therapeutic-approaches-in-sight
#9
Claudia M Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Chiara Riganti, Piero Picci, Massimo Serra
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28183193/recent-advances-in-clinical-studies-and-the-evolving-role-of-subtyping-for-patients-with-diffuse-large-b-cell-lymphoma
#10
Grzegorz S Nowakowski, Umberto Vitolo
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28183191/bladder-cancer-immunotherapy-swinging-for-the-fences
#11
Fouad Aoun, Elie El Rassy, Alexandre Peltier
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28183189/what-advances-have-been-made-in-immune-therapy-for-renal-cell-carcinoma
#12
Elena Verzoni, Paolo Grassi, Raffaele Ratta
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28152619/a-multinational-report-of-technical-factors-on-stereotactic-body-radiotherapy-for-oligometastases
#13
Kristin J Redmond, Simon S Lo, Roi Dagan, Ian Poon, Matthew C Foote, Darby Erler, Young Lee, Frank Lohr, Tithi Biswas, Umberto Ricardi, Arjun Sahgal
AIM: Oligometastatic cancer is being increasingly managed with aggressive local therapy using stereotactic body radiation therapy (SBRT). However, few guidelines exist. We summarize the results of an international survey reviewing technical factors for extracranial SBRT for oligometastatic disease to guide safe management. MATERIALS & METHODS: Seven high-volume centers contributed. Levels of agreement were categorized as strong (6-7 common responses), moderate (4-5), low (2-3) or no agreement...
February 3, 2017: Future Oncology
https://www.readbyqxmd.com/read/28147707/activity-of-chemokines-in-prostate-and-renal-tumors-and-their-potential-role-as-future-therapeutic-targets
#14
Alessia Cimadamore, Marina Scarpelli, Francesco Piva, Francesco Massari, Silvia Gasparrini, Andrea Doria, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi
Chemokines are a class of low-molecular-weight proteins that induce chemotaxis and are implicated in the modulation of angiogenesis. The imbalance among angiogenic and antiangiogenic chemokines can promote the development of several conditions, including chronic inflammation, dysplastic transformation and cancer. In this review, we describe the activity and clinical significance of chemokines in prostate and renal tumors and provide an update on ongoing studies in this setting.
February 2, 2017: Future Oncology
https://www.readbyqxmd.com/read/28125906/difluoromethylornithine-in-cancer-new-advances
#15
George A Alexiou, Georgios D Lianos, Vassileios Ragos, Vasiliki Galani, Athanassios P Kyritsis
Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis. Polyamines are important for cell survival, thus DFMO was studied as an anticancer agent and as a chemoprevention agent. DFMO exhibited mainly cytostatic activity and had single agent efficacy as well as activity in combination with other chemotherapeutic drugs for some cancers and leukemias. Herewith, we summarize the current knowledge of the anticancer and chemopreventive properties of DFMO and assess the status of clinical trials...
January 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28110557/preparation-and-biological-evaluation-of-99m-tc-hynic-ser-3-d4-peptide-for-targeting-and-imaging-of-non-small-cell-lung-cancer
#16
Mona Haddad Zahmatkesh, Seyed Mohammad Abedi, Seyed Jalal Hosseinimehr
AIM: In this study, radiolabeled D4 peptide conjugate was studied as a radiotracer for imaging of non-small-cell lung cancer with overexpression of EGFR. METHODS: HYNIC-(Ser)3-D4 peptide was labeled with (99m)Tc using tricine as a co-ligand. Cellular specific binding and internalization as well as in vivo tumor targeting were assessed. RESULTS: The in vitro experiments showed good cellular specific binding. Tumor uptake values as %ID/g were 7...
January 23, 2017: Future Oncology
https://www.readbyqxmd.com/read/28110551/primary-tumor-site-and-anti-egfr-monoclonal-antibody-benefit-in-metastatic-colorectal-cancer-a-meta-analysis
#17
Dandan Li, Qiang Fu, Man Li, Jun Li, Can Yin, Jin Zhao, Feng Li
AIM: This meta-analysis aimed to document the impact of primary tumor site on anti-EGFR monoclonal antibody (mAb) benefit in metastatic colorectal cancer. MATERIALS & METHODS: Tumors with metastatic left-sided colorectal cancer (LCC) were compared with tumors with metastatic right-sided colon cancer (RCC) with respect to anti-EGFR mAb objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) benefit. RESULTS: Comparing LCC with RCC, LCC was found to have significantly superior anti-EGFR mAb ORR (p < 0...
January 23, 2017: Future Oncology
https://www.readbyqxmd.com/read/28095720/baseline-chromogranin-a-and-its-dynamics-are-prognostic-markers-in-gastroenteropancreatic-neuroendocrine-tumors
#18
Wojciech Rogowski, Ewa Wachuła, Anna Lewczuk, Agnieszka Kolesińska-Ćwikła, Ewa Iżycka-Świeszewska, Violetta Sulżyc-Bielicka, Jarosław B Ćwikła
AIM: This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with (90)Y-[DOTA(0), D-Phe(1), Tyr(3)]-octreotate. PATIENTS & METHODS: CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of (90)Y-[DOTA(0), D-Phe(1), Tyr(3)]-octreotate...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28095710/the-evolving-role-of-chemotherapy-in-prostate-cancer
#19
Suliman Boulos, Danish Mazhar
Despite extensive clinical research of different chemotherapy agents for more than three decades, the role of chemotherapy in prostate cancer was only established in 2004, after demonstrating a survival benefit with docetaxel in metastatic castration-resistant prostate cancer. 6 years later, second-line chemotherapy using cabazitaxel, after disease progression on docetaxel, demonstrated an additional survival improvement. Recently, docetaxel given alongside standard hormonal therapy in newly diagnosed advanced prostate cancer was found to lead to significantly improved patient outcomes...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28088872/prognostic-prediction-by-liver-tissue-proteomic-profiling-in-patients-with-colorectal-liver-metastases
#20
Adalgiza Reyes, Josep Marti, Santiago Marfà, Wladimiro Jiménez, Vedrana Reichenbach, Amalia Pelegrina, Constantino Fondevila, Juan Carlos Garcia Valdecasas, Josep Fuster
AIM: To obtain proteomic profiles in patients with colorectal liver metastases (CRLM) and identify the relationship between profiles and the prognosis of CRLM patients. MATERIALS & METHODS: Prognosis prediction (favorable or unfavorable according to Fong's score) by a classification and regression tree algorithm of surface-enhanced laser desorption/ionization TOF-MS proteomic profiles from cryopreserved CRLM (patients) and normal liver tissue (controls). RESULTS: The protein peak 7371 m/z showed the clearest differences between CRLM and control groups (94...
January 16, 2017: Future Oncology
journal
journal
41162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"